Generic semaglutide clears Health Canada for second time

The second generic semaglutide approval in Canada signals that Health Canada is prepared to evaluate complex GLP-1 injectable submissions at scale, a development that will sharpen scrutiny on comparability data, device compatibility, and sterility assurance standards across the North American supply chain.

OneSource Specialty Pharma clears Health Canada for generic semaglutide

OneSource Specialty Pharma has received Health Canada approval for a generic version of semaglutide injection, the active ingredient in Novo Nordisk's Ozempic. The clearance marks the second generic semaglutide approval issued by Health Canada, establishing a nascent but growing competitive field in Canada's GLP-1 injectable market.

The approval positions OneSource within the complex injectable CDMO segment, a space that demands robust process validation, demonstrated device-drug compatibility, and full alignment with 21 CFR Part 211 equivalents under Canada's Food and Drug Regulations. For a molecule of semaglutide's complexity, regulatory clearance also implies successful bioequivalence demonstration and acceptable comparability to the reference listed drug.

Where QA directors and CMC teams should review their GLP-1 dossiers

For manufacturers and CDMOs already developing GLP-1 injectable programs, the OneSource clearance is a reference point on what Health Canada will accept at the dossier level. The approval reinforces that complex peptide injectables are no longer exclusively the domain of originator manufacturers, but the bar for sterility assurance, container closure integrity, and formulation stability remains high.

Supply-chain leads evaluating North American generic semaglutide sourcing should note that a second approved supplier increases optionality, though commercial scale-up timelines and capacity commitments will determine actual availability. ICH Q10-aligned pharmaceutical quality systems will be a baseline expectation for any CDMO entering this space at volume.

Tracking Health Canada's GLP-1 generic pipeline through 2026

With two generic semaglutide approvals now on record, Health Canada's review posture on subsequent submissions will be closely watched by regulatory affairs leads benchmarking their own dossier timelines. The agency's willingness to clear a second entrant suggests the comparative review framework for GLP-1 injectables is becoming more defined, which may accelerate review cycles for submissions already in queue.

Regulatory leads should monitor Health Canada's Drug Product Database for additional semaglutide entries and track any updated guidance on complex injectable bioequivalence that may follow from this approval pattern.

The commercial and regulatory trajectory of generic semaglutide in Canada will become clearer as Health Canada processes remaining submissions in its GLP-1 injectable queue through the remainder of 2026.